These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 16421900)

  • 1. EBV lymphoproliferative disease of host origin after haploidentical stem cell transplantation.
    Kasow KA; Leung W; Horwitz EM; Woodard P; Handgretinger R; Hale GA
    Pediatr Blood Cancer; 2007 Nov; 49(6):869-72. PubMed ID: 16421900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Examining the origin of posttransplant lymphoproliferative disorder in a patient after a second allogeneic hematopoeitic stem cell transplantation for relapsed BCR-ABL positive acute lymphoblastic leukemia.
    Ruf S; Moser O; Wössmann W; Kreyenberg H; Wagner HJ
    J Pediatr Hematol Oncol; 2011 Jan; 33(1):50-4. PubMed ID: 21178708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of rituximab and irradiated donor-derived lymphocytes to control Epstein-Barr virus-associated lymphoproliferation in patients undergoing related haplo-identical stem cell transplantation.
    McGuirk JP; Seropian S; Howe G; Smith B; Stoddart L; Cooper DL
    Bone Marrow Transplant; 1999 Dec; 24(11):1253-8. PubMed ID: 10642818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction.
    Kinch A; Oberg G; Arvidson J; Falk KI; Linde A; Pauksens K
    Scand J Infect Dis; 2007; 39(3):235-44. PubMed ID: 17366054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Epstein-Barr virus-associated post-transplant lymphoproliferative disorder diagnosed by the episode of intestinal perforation following allogeneic hematopoietic stem cell transplantation].
    Aimoto M; Yamane T; Inoue A; Momose D; Moriguchi-Aimoto R; Wada-Inoue E; Okamoto S; Koh H; Nakane T; Takeoka Y; Akahori-Nakamae M; Nishiki-Kosaka S; Terada Y; Nakamae H; Koh KR; Nakao T; Ohsawa M; Hino M
    Rinsho Ketsueki; 2010 Dec; 51(12):1775-80. PubMed ID: 21258188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of treatment of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases.
    Styczynski J; Einsele H; Gil L; Ljungman P
    Transpl Infect Dis; 2009 Oct; 11(5):383-92. PubMed ID: 19558376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor origin and CD20 expression in posttransplant lymphoproliferative disorder occurring in solid organ transplant recipients: implications for immune-based therapy.
    Gulley ML; Swinnen LJ; Plaisance KT; Schnell C; Grogan TM; Schneider BG;
    Transplantation; 2003 Sep; 76(6):959-64. PubMed ID: 14508361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epstein-Barr virus reactivation in allogeneic stem cell transplantation is highly related to cytomegalovirus reactivation.
    Zallio F; Primon V; Tamiazzo S; Pini M; Baraldi A; Corsetti MT; Gotta F; Bertassello C; Salvi F; Rocchetti A; Levis A
    Clin Transplant; 2013; 27(4):E491-7. PubMed ID: 23781897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytomegalovirus and Epstein-Barr virus-associated post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation.
    Tsao SY; Chang KC; Chen YP; Yeh YM; Su WC; Chen TY
    Ann Hematol; 2011 Jan; 90(1):113-4. PubMed ID: 20369358
    [No Abstract]   [Full Text] [Related]  

  • 10. Monitoring of Epstein-Barr virus load after hematopoietic stem cell transplantation for early intervention in post-transplant lymphoproliferative disease.
    Meerbach A; Wutzler P; Häfer R; Zintl F; Gruhn B
    J Med Virol; 2008 Mar; 80(3):441-54. PubMed ID: 18205222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of monitoring Epstein-Barr virus PCR in paediatric bone marrow transplant patients: can it successfully predict outcome and guide intervention?
    Greenfield HM; Gharib MI; Turner AJ; Guiver M; Carr T; Will AM; Wynn RF
    Pediatr Blood Cancer; 2006 Aug; 47(2):200-5. PubMed ID: 16206207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unmanipulated donor lymphocytes for EBV-related PTLD after T-cell depleted HLA-haploidentical transplantation.
    De Pasquale MD; Mastronuzzi A; De Vito R; Cometa A; Inserra A; Russo C; De Ioris MA; Locatelli F
    Pediatrics; 2012 Jan; 129(1):e189-94. PubMed ID: 22144701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic hematopoietic stem cell transplantation for Epstein-Barr virus-associated T/natural killer-cell lymphoproliferative disease in Japan.
    Sato E; Ohga S; Kuroda H; Yoshiba F; Nishimura M; Nagasawa M; Inoue M; Kawa K
    Am J Hematol; 2008 Sep; 83(9):721-7. PubMed ID: 18626884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Epstein-Barr virus-associated pneumonia in patients with post-transplant lymphoproliferative disease after hematopoietic stem cell transplantation].
    Liu QF; Fan ZP; Luo XD; Zhang Y; Sun J
    Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(44):3123-6. PubMed ID: 19159594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epstein-Barr virus polymerase chain reaction-negative stage IV post-transplant lymphoproliferative disorder in a heart transplant patient treated with rituximab.
    Garceau P; Couture C; Cantin B; Bernier V; Sénéchal M
    J Heart Lung Transplant; 2008 Aug; 27(8):928-31. PubMed ID: 18656811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epstein-Barr virus-associated lymphoproliferative disease after allogeneic haematopoietic stem cell transplantation: molecular monitoring and early treatment of high-risk patients.
    Meijer E; Cornelissen JJ
    Curr Opin Hematol; 2008 Nov; 15(6):576-85. PubMed ID: 18832928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-emptive therapy with rituximab for prevention of Epstein-Barr virus-associated lymphoproliferative disease after hematopoietic stem cell transplantation.
    Gruhn B; Meerbach A; Häfer R; Zell R; Wutzler P; Zintl F
    Bone Marrow Transplant; 2003 Jun; 31(11):1023-5. PubMed ID: 12774054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fatal donor-derived Epstein-Barr virus-associated post-transplant lymphoproliferative disorder following reduced intensity volunteer-unrelated bone marrow transplant for myelodysplastic syndrome.
    Ho AY; Adams S; Shaikh H; Pagliuca A; Devereux S; Mufti GJ
    Bone Marrow Transplant; 2002 May; 29(10):867-9. PubMed ID: 12058237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epstein-Barr virus-associated pneumonia in patients with post-transplant lymphoproliferative disease after hematopoietic stem cell transplantation.
    Liu QF; Fan ZP; Luo XD; Sun J; Zhang Y; Ding YQ
    Transpl Infect Dis; 2010 Aug; 12(4):284-91. PubMed ID: 20345506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab treatment for Epstein-Barr virus DNAemia after alternative-donor hematopoietic stem cell transplantation.
    Coppoletta S; Tedone E; Galano B; Soracco M; Raiola AM; Lamparelli T; Gualandi F; Bregante S; Ibatici A; di Grazia C; Dominietto A; Varaldo R; Bruno B; Frassoni F; Van Lint MT; Bacigalupo A
    Biol Blood Marrow Transplant; 2011 Jun; 17(6):901-7. PubMed ID: 20950702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.